BLAIRSTOWN TOWNSHIP, N.J. – A molar root that weighed just 200 milligrams was the key to identifying a teen who was brutally murdered nearly 40 years ago.
Prosecutors in New Jersey announced on Friday (July 15) that the teen only known as “Princess Doe” had been identified as Dawn Olanick.
Olanick’s body was found exactly 40 years ago, on July 15, 1982 in a New Jersey cemetery. Her face had been beaten so severely that she could not be identified.
Olanick was 17 years old when she was killed. Prosecutors have charged Arthur Kinlaw with her murder. Kinlaw is currently in prison for a different murder.
“This is a very big deal for my family,” said Olanick’s cousin. “I’d like to thank Blairstown for treating my cousin like she was one of their own. It touches our family deeply . . . my cousin is always in my heart.”
How DNA cracked the case
Olanick was the first unidentified persons’ case to be entered into the National Crime Information Center. The National Center for Missing and Exploited Children helped submit Olanick’s molar and eyelash to Astrea Forensics in 2021 for DNA testing.
“What is so special about Astrea is that they are able to extract DNA from samples that are degraded or otherwise would provide no value,” said Carol Schweitzer, a forensic supervisor at NCMEC. “We knew that if anyone could get the information that was needed, Astrea could.”
Kelly Kincaid, CEO of Astrea Forensics, told NCMEC that the DNA was well preserved and they were able to complete the DNA profile with it.
“This single DNA extract contained hundreds of millions of unique human DNA fragments,” said Kincaid. “With these sequencing data we were able to reconstruct [her] whole genome single Nucleotide Polymorphisms (SNP) profile. This resulted in Astrea being able to deliver genotype files to NCMEC and the Warren County Prosecutor’s Office that could go on and be used to complete Princess Doe’s genealogy.”
Innovative Forensic Investigations (IFI) worked on investigative genetic genealogy to build a family tree. That led to investigators identifying Olanick.
“This work was only possible because of the collaborative effort of each agency,” said Jennifer Moore, CEO of IFI. “Our team brings forward a diverse set of skills that allows us to help find answers to cases.”
SOUTH PITTSBURG, Tenn. — After nearly four decades, a man’s body found in Tennessee off Interstate 24 near South Pittsburg has a name and a missing Georgia man’s family has an answer.
Donald Boardman had been a question mark after vanishing 37 years ago and his body would have remained a “John Doe” if not for a steadfast investigator who never gave up on the case, a curious stay-at-home mom who scratched out a trail to his identity and a Georgia criminal analyst who was in the right place when the decades-old cold case started coming together.
Boardman was a snappy dresser with a new 1985 Chevrolet Camaro Z28 when he disappeared following an event at the Atlanta Convention Center. Then the body of an unknown well-dressed man was found in Tennessee with no name and no family.
(READ MORE: TBI, Grundy County authorities tracking new leads in 1999 cold case disappearance of Tim White)
The investigation into Boardman’s disappearance — reported after he was last heard from Nov. 16, 1985, in Chamblee, Georgia — grew cold over the years until 2018, when a Sewanee, Tennessee, woman spotted a Chattanooga Times Free Press story on social media that roused her curiosity.
An intriguing story
The article was about a cold case that 12th Judicial District Attorney’s Office investigator Larry B. Davis wanted to revive in hopes of putting a name to a half-skeletal body discovered by an angler in 1985 along a Marion County creek just a few steps from I-24.
The story was on two bodies discovered in the mid-1980s, one that was identified not long after it was discovered and another that would eventually be identified as Boardman, believed initially to have been linked by a common killer to each other and other bodies that were found in those years across Southeast Tennessee.
While skeletal from the waist up, the unidentified body was clad in an expensive Oxford cloth shirt and new Jordache blue jeans, Davis said recently in an interview at the District Attorney’s Office in Dayton, Tennessee.
In 1985, William M. Bass at the University of Tennessee Forensic Anthropology Center determined the body had been where it was found Dec. 16, 1985, for about 30 days, a period Davis said was accurate relative to the date authorities later learned Boardman had last spoken to his family. Bass and Lee Jantz, the center’s associate director, were instrumental in collecting the evidence that would help later help identify Boardman, Davis said.
Davis, 69, was 32 when he was part of the original investigation in 1985. He said it lingered in his mind because he knew there was a family somewhere that didn’t know what happened to their loved one. In December 2017, he approached the Times Free Press to work on a story about the cold case that ran Jan. 29, 2018.
Sewanee resident Barbara King Ladd spotted the Times Free Press story on her Facebook feed.
Ladd, who works for the Franklin County school system and in the past worked for the local judicial district’s drug court, said divine guidance was at work.
“From my perspective, God obviously put this case on Larry’s heart,” Ladd said recently in a telephone interview.
After reading about the case, Ladd said God had put Boardman’s case on her heart, too.
“I found the story in my Facebook feed, so I clicked on it and read it and then it put it on my heart and piqued my curiosity, and if something grabs my curiosity, I will follow it through until it gets boring to me,” she said.
Ladd, 43, began combing through missing persons websites for likely candidates based on information in the Times Free Press article. She said she was a stay-at-home mom at the time with lots of time for internet sleuthing.
“The forensic sketch and the picture of Donald Boardman was just perfect,” she said of when she found intriguing information on a missing persons website that seemed to have similarities to the body in Marion County.
As she searched Boardman’s name in a portion of another news story, Ladd found a detective connected with the case, but she didn’t immediately see the agency he worked for, she said. There was information about Boardman living in DeKalb County, Georgia, his identification and some clothing being found inside his car that had been reported stolen, she said.
(READ MORE: Investigators identify Dade County homicide victim after nearly 34 years)
She was increasingly convinced she was on the right trail.
Ladd said no more than a day or two after reading the story she sent a couple of emails to the 12th Judicial District Attorney’s Office but they’d gone unread, she initially decided.
But soon, Davis emailed back about the Boardman information and told her he had taken that information to Tennessee Bureau of Investigation’s Fusion Center in Nashville, but she never heard anything back after that. In Tennessee, the information met a dead end for lack of fingerprints or DNA evidence at the time to link to anyone, so the case idled, according to investigators.
“That’s when I said, I’m going to take all this information and send it directly to Chamblee,” Ladd said.
In late April 2021, Ladd decided to send the Marion County information through a Facebook message to Chamblee police.
“I intentionally decided to send it through Facebook so that the person who received it would know it was a real person and see my picture and know that I wasn’t crazy,” she said. “I think it was God’s hand again that the message went to Lori [Bradburn], who read the information and became interested in it.”
Chamblee Police Department criminal analyst Lori Bradburn was performing a routine check that day on the department Facebook page.
“I got a random message on our police department’s Facebook page that said, ‘I am pretty sure I have information regarding this cold case,'” Bradburn said during a recent interview at the 12th Judicial District Attorney’s Office in Dayton.
Bradburn, 34, unfamiliar with the 1985 investigation, started taking a new look at the case file and compared her information with the case details in the Times Free Press story.
Bradburn then began digging for case information on her end and got in touch with Davis to compare notes that would lead to answers, she said.
During the interview in Dayton, District Attorney Mike Taylor said help from the public is a common key to solving mysteries like Boardman’s.
“I personally commend the private citizen who gave her time and resources to help us a tremendous amount in solving this case. She did her civic duty and became involved of her own free will,” Taylor said.
Davis credits Ladd for her persistence.
“I’m so glad she went to the source and gave her thoughts to Lori,” Davis said. “If she hadn’t, I’d still be looking for Donald.”
Ladd said she was glad to have played a part along with the investigators and family.
“I think it’s really cool that God used me to play a part in this. It’s one of the coolest things that God has ever included me in,” she said.
“There’s Larry, who had the sense to get a really great forensic drawing of him and to over the years keep pushing the case so it wasn’t a dead file, right? Then he had the notion to contact you [the Times Free Press] to do the article,” Ladd said.
Bradburn and Davis began fitting the pieces together from case information going back more than 30 years.
According to a 1985 Chamblee Police Department report, Harry Boardman, Donald’s father, filed a missing person report Nov. 19, 1985, stating the last time he spoke with his son was three days earlier on the night of Nov. 16, 1985. Boardman’s employer at his new job in Atlanta at Miller and Zell Designs also hadn’t seen him since that same day.
The Chamblee police report said Boardman had a 1985 Chevrolet Camaro Z28. Chamblee police would soon hear from police in East Point, Georgia, where Boardman’s car turned up in the possession of three people, two of whom had extensive criminal records, according to Bradburn and the report.
(READ MORE: Dunlap police hire help in 2018 missing persons cases as authorities say there are persons of interest)
On Nov. 29, 1985, an East Point police 0fficer saw two men and a woman who appeared intoxicated get into a 1985 Camaro bearing Boardman’s license plate that was parked at a barbecue restaurant. The tag was identified as being registered to a car that had been reported stolen to Chamblee police, according to the East Point police report.
“The tag info had revealed that the vehicle was wanted by Chamblee P.D. in connection with a missing person, foul play suspected,” the report states.
The male driver and the two passengers were detained by police while their names were checked for active warrants. The woman was found to have an outstanding warrant on a charge of armed robbery in Atlanta, the report states.
The three were detained for questioning by Chamblee police. East Point officers while searching Boardman’s Camaro found a Visa card with Boardman’s name on it under the left rear seat where the male passenger had been sitting, according to the report.
Investigators at the time sought connections between the missing man and the trio found with his car and found Boardman’s Visa was used after he was reported missing to make a variety of purchases from gas stations, two department stores and two Chevrolet dealerships, according to 1985 police reports.
Other purchases using the card were made at a motorcycle salvage shop with descriptions matching the trio found with Boardman’s car, the reports state. Since 1985, the two men have died but the woman still lives.
Bradburn said Saturday she has found no evidence or documents indicating the three were charged in connection with the matter. She’s still doing a deep dive into police records, and investigators are looking ahead to next steps.
After joining forces, Bradburn and Davis decided last summer to contact Boardman’s sister and work toward a DNA test.
The forensic center in Knoxville in 2009 extracted DNA from a tooth, and after Bradburn contacted Davis in July 2021, the two were convinced it was time to find one of Boardman’s family members for testing.
He had only one, a sister, and her DNA matched the body’s in a mitochondrial test performed late in 2021, but Taylor and Jantz wanted a more conclusive “short random repeat” test, which is a form of DNA testing that yields high match statistics, according to officials.
The final word on that test came in February, when the more definitive test resulted in a match confirming Boardman’s identity.
Sister has answers
In Plantation, Florida, Debbie Boardman Anderson, now 70, has waited most of her adult life for an answer, she said in telephone interviews Wednesday and Thursday.
Anderson was more than stunned by the news it was possible her brother’s body had been found.
“Larry Davis called in July. I know they had been working on it, but for me, it was out of the clear blue sky. I was not expecting it,” she said. “There were so many things going through my mind — shock, happiness, relief and grief all at the same time. I was sobbing on the phone. I put down the phone, and I went and told my husband, Mike.”
(READ MORE: Cleveland man identified as murder suspect in 1985 cold case slaying)
Anderson had been in a minor car accident the week before. At the moment Davis called, she and her husband were getting ready to go pick up a rental car, she said. Those plans and the previous week evaporated from her mind.
“I got immediate amnesia at that point,” she said, “and I was told afterwards that it could be a combination of minor head trauma and stress, hearing some incredibly stressful news.
“I mean, amnesia? That’s something you see in the movies.”
Anderson suddenly couldn’t recall the accident or the plans to get a rental car.
“For two or three hours, my husband said I had no clue what was going on,” she said. “He took me downstairs and showed me the car, and I said, ‘Oh, my God, what happened? What happened to our brand-new Tesla?'”
She regained her composure after a few hours, she said.
Anderson said she thought she would never know what happened to her brother.
The last time the family heard from him was in November 1985.
“It was right before Thanksgiving, and he had just talked to my mother about coming home for Thanksgiving,” she said. “He told her he was going to the convention center in Atlanta to go to a health food show. He was very into eating healthy, and that’s what he did that night.”
The family expected to see him soon, but they instead got a call from her brother’s employer, who told them Donald Boardman hadn’t shown up for work.
“I just told my husband that I’ve always had a sixth sense about my brother. I knew him really well, and I just knew something was wrong,” she said of her thoughts at the time. “It was a new job, and he loved it. He couldn’t wait to go to work. He’d just gotten a new car.”
(READ MORE: 20-year-old cold case of Chattanooga boy’s killing reopened with help of FBI)
She said her brother’s personality might have made him vulnerable.
“What’s so frustrating about this is my brother was just such a nice guy, and he probably couldn’t believe what was going on,” Anderson said. “Thank goodness I’m still alive. I’ve carried this with me since I first got married. I’m so sorry for my mom and my dad, who never knew.”
Even though she and her parents knew their missing loved one was most likely dead, not knowing was torturous. Now she can lay her brother to rest, she said.
Anderson said she is grateful to Davis and the forensic center holding her brother’s body over the decades.
“I really appreciate what everyone’s done in Tennessee,” she said.
Anderson praises Davis for sticking with the case over the years, reviving it in 2018 so the connections from Davis to Ladd to Bradburn could be made to link her brother’s disappearance in Georgia to the creekside scene in Tennessee.
Ladd had a good eye for detail to see the resemblance in the forensic sketch that went with the 2018 newspaper story, Anderson said.
“It was finally time for everything to happen,” she said.
Her brother will come home soon.
“I’m going to have a memorial at sea,” she said. No date has been, set but Anderson hopes everyone involved in the case can attend when the time comes.
It’s a three-decade-old, high-profile murder case that has received national attention.
The person in the below composite sketch is the man investigators believe is the I-70 Serial Killer.
The sketches below are age-enhanced. These show what the killer could look like now.
According to police, six store clerks along Interstate 70 were killed in a murder spree over 29 days. Two in Indiana, two in Kansas and two in Illinois.
Detectives said the scenario for all six murders was basically the same. The killer walked in, shot the clerk in the back of the head and then left all in broad daylight, all with the same gun.
Terre Haute Police Detective Sergeant Troy Davis has been working on this case for more than ten years. The three-state killing spree claimed six lives – one in Terre Haute.
“I certainly wouldn’t call it a cold case now,” Davis said. “Even after 30 years, you might think people would get over it, but they don’t, they don’t get over it.”
Michael “Mick” McCown – Terre Haute’s victim
On April 27, 1992, the I-70 killer claimed the life of 40-year-old Michael “Mick” McCown. He was working as a store clerk at his family’s ceramics store.
This was on south 3rd Street in Terre Haute.
According to police, McCown was the I-70 Killer’s only male victim.
Davis stays connected with McCown’s family.
“When I see them (McCown’s family), especially when they get emotional…they still get emotional after 30 years, and that’s something that affects you,” Davis said.
Heating back up
Terre Haute Police Detective Brad Rumsey says he believes his department has an edge in solving this case.
“There’s no reason not to be focused on him, but you don’t want to put all of your eggs in one basket. There’s always the possibility that this sketch could be off,” Rumsey said. “Maybe it’s one of those deals where someone was in the wrong place at the wrong time. You have to count on other things, not just the picture.”
The other things include the fact that the killer used a unique gun to shoot his victims. Ballistics link the deaths.
All of the agencies involved in this investigation have sent items away for DNA testing. Investigators hope DNA matches up and there’s a connection.
Davis says he’s witnessed firsthand this cold case warming back up in the last two years. Heat brought on by all the law enforcement agencies investigating the case.
Davis says, yes, they have a facial composite of the suspect, and ballistics link the deaths, but they need more. That’s where advancements in technology come in.
All agencies working on this mystery have evidence that’s been sent away for DNA testing. The results from the testing could lead to the killer’s identity.
Davis says the hard part is waiting – but he believes Terre Haute could solve the case.
All of the agencies involved in this investigation have sent items away for DNA testing. Investigators hope DNA matches up and there’s a connection.
Rumsey says the THPD has never given up. He says the families deserve closure.
“When you let a case go cold because of the evidence…or lack thereof…you get antsy. You want to move forward,” Rumsey said. “For me, it just means we are still behind the eight-ball. We need to get there.”
He told us tips from the public continue to move this case forward. An information portal was created for all of the agencies involved.
Davis told News 10 that around eight to ten tips are received each week.
You can share information by calling 1-800-800-3510 or by clicking here.
BERKELEY, Calif. and MAINZ, Germany, April 12, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today operational results for the first quarter ended March 31, 2022.
Continued to ramp up EU commercial activities for ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancerAcquired portfolio of novel mRNA biomarkers to potentially upgrade ColoAlert’s technical profile to achieve “gold standard” status for CRC at-home testingCommenced international clinical study (ColoFuture) to evaluate integration of these biomarkers into ColoAlertReceived supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trialFormally initiated ColoAlert’s U.S. medical reimbursement process with the Centers for Medicare Services (CMS)Executed a $25.8 million public follow-on offeringExpanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization
“This past quarter has proven to be an excellent period of progress across commercial, corporate and product development fronts,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The entire Mainz team is excited by the rapid growth achieved to date and remains steadfast in our conviction to advance an ambitious yet balanced strategy to maximize ColoAlert’s potential in the marketplace, and to build our oncology-focused diagnostic franchise via a unique commercial model and robust technical approach to product development.”
Commercial Update: ColoAlert marketed across Europe via unique business model During the quarter, Mainz continued its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. Under the standard terms of all partnerships, Mainz is providing ColoAlert to the respective labs, including co-branding with key accounts, whereby each facility purchases Mainz’s customized polymerase chain reaction (PCR) assay kits on an on-demand basis and provides to their respective network of physicians and patients a comprehensive solution for advanced CRC protection. During the first quarter (February 2022), Mainz announced a partnership with Labor MVZ Dr. Stein + Kollegen (“Laboratory Mönchengladbach”), one of the largest diagnostics laboratories in the North Rhine-Westphalia region of Germany. The Lab services over 2,500 physicians, processing over five million samples in total annually and screening approximately 1,000 patients per week specifically for CRC. With the addition of Laboratory Mönchengladbach, Mainz now has four core partnerships including GANZIMMUN Diagnostics AG, one of Europe’s leading laboratories for preventive and complementary medicine which processes approximately 5,500 laboratory orders daily.
ColoAlert R&D Update: ColoFuture study evaluating acquired mRNA biomarkers In February 2022, Mainz initiated a clinical study (ColoFuture) to evaluate a portfolio of five gene expression biomarkers acquired from Socpra Sciences Santé Et Humaines S.E.C. in January 2022. The results from a published study in the peer review journal MDPI (March 11, 2021) demonstrated that these specific biomarkers have a high degree of effectiveness in detecting CRC lesions including advanced adenomas (“AA”), a type of pre-cancerous polyp often attributed to this deadly disease. As such, the ColoFuture study will determine if the biomarkers enhance ColoAlert’s technical profile to extend its capability to include the identification of advanced adenomas (AA) while increasing ColoAlert’s rates of diagnostic sensitivity and specificity. If the data results from ColoFuture are successful, ColoAlert will be positioned as the most robust and accurate at-home diagnostic screening test on the market, as it will not only detect cancerous polyps with a high degree of accuracy but has the potential to prevent CRC through early detection of precancerous adenomas.
To ensure optimal study execution, the Company announced during the first quarter strategic partnerships with Sentinel Diagnostics and Alcedis GmbH. Sentinel Diagnostics is a global leader in the development and production of in vitro diagnostics (IVD), and Alcedis GmbH is a full-service state-of-the-art contract research organization (CRO) providing clinical trial management for biotechnology and medical device companies across the globe. With Sentinel, Mainz has been granted access to the SENTiFIT® 270 Analyzer, Sentinel’s leading automated Fecal Immunochemical Test (FIT) processing system. An essential component of ColoAlert is the utilization of a FIT which provides a complete review of blood in the stool, a condition often associated with cancerous polyps and colorectal carcinoma. It is the combination of ColoAlert and FIT results that provide the diagnostic outcome. This partnership enables Mainz to transition from deploying a manual FIT processing methodology to a state-of-the-art automated system for potential future use in the EU commercial setting, and in the Company’s forthcoming U.S. clinical trial. Alcedis is providing Mainz with the full range of services and responsibilities associated with executing ColoFuture, including patient recruitment, overseeing study protocol compliance, and the documentation and reporting of patient results.
The ColoFuture study will enroll over 600 patients in the age range of 40-85 at two participating centers in Norway and two in Germany. The Company expects to complete enrollment during the second half of 2022 and is targeting reporting study results in early 2023. Additionally, data results from ColoFuture will impact ColoAlert’s profile for FDA submission.
ColoAlert’s U.S. Regulatory Approval Update: Pre-submission for pivotal trial design receives feedback from the FDA and medical reimbursement process launched with CMS In March 2022, Mainz announced that it received supportive feedback from the U.S. Food & Drug Administration on its pre-submission package for ColoAlert. The Company will continue working with its clinical team to finalize the study’s protocols and prepare for the multi-center study which is on track to commence in late 2022. As part of the Company’s activities to prepare for the initiation of the pivotal trial, Mainz also announced the formal commencement of its medical reimbursement process for ColoAlert by scheduling an initial meeting with the Centers for Medicare and Medicaid Services (CMS) which is set to take place in April 2022. CMS is a federal agency in the U.S. Department of Health and Human Services (HHS) that administers the Medicare program and works in partnership with state governments to administer Medicaid, the Children’s Health Insurance Program (CHIP), and health insurance portability standards.
Corporate Update: Successful follow-on offering, key appointments to management team & Strategic Advisory Board. In January 2022, the Company announced a $25.8 million public follow-on offering consisting of 1,725,000 of ordinary shares priced at $15.00 per share. Boustead Securities, LLC acted as the sole underwriter for the transaction. The Company plans to file its Report on Form 20-F, including audited financial statements for 2021, with the U.S. Securities and Exchange Commission in April 2022.
Throughout the first quarter, the Company continued to bolster its leadership team highlighted by the appointments of former Abbott Diagnostics executive Steve Quinn as Vice President of Business Development (January) along with the two high profile additions to Mainz’s Strategic Advisory Board. In January, Dr. Michele Pedrocchi joined the SAB followed by the February appointment of Dr. Rainer Metzger. Dr. Pedrocchi is the former Head of Roche Diagnostics Business Development and brings to the SAB over 25 years of international experience at Roche spanning in vitro diagnostics, digital health, and personalized medicine. Dr. Metzger is a Former Danaher, Roche and Qiagen Executive with over 25 years of experience within the pharmaceutical and diagnostic industries.
About ColoAlert ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the European Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country. * Dollinger MM et al. (2018)
About Colorectal Cancer Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late-stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimates that in 2021 there will be approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death. Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the US should be conducted once every three years starting at age 45. Currently, there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these US-based 50+ populations every three years as prescribed equates to a US market opportunity of approximately $3.7 Billion per year.
About Mainz Biomed N.V. Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.
For more information, please visit www.mainzbiomed.com
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its registration statement on Form F-1 filed on January 21, 2022. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
Houston, April 05, 2022 (GLOBE NEWSWIRE) — NuProbe, a global genomics and molecular diagnostics company, announced new published data in Nature Communications describing the use of Quantitative Amplicon Sequencing (QASeq) to simultaneously detect copy number variations (CNVs) and mutations from the same sample. The results show detection of CNVs down to 5% heterozygous single copy gain or loss, and mutations down to 0.1% variant allele frequency (VAF), from both formalin-fixed, paraffin-embedded (FFPE) tissue samples and from cell-free DNA (cfDNA) samples.
Watch a video about the mechanism and learn more about QASeq.
CNVs are an important class of DNA biomarkers for cancer. Depending on the exact type of cancer, CNVs can be present in up to 98% of patients and can influence therapy selection and prognosis prediction. CNVs are currently detected using fluorescence in situ hybridization (FISH) or digital droplet PCR (ddPCR). However, these methods are limited in their multiplexing, and typically no more than about four genes can be profiled for CNVs with these methods. Furthermore, these methods cannot be used for profiling DNA mutations from the same samples. Consequently, comprehensive DNA profiling of many genes would require larger input quantities of patient DNA, which are often not available.
“By achieving higher analytical sensitivity for multi-gene CNV panels, QASeq has the potential to improve the clinical sensitivity in CNV assessment,” says Peng Dai, co-first author of the study. “Our collaborations with Drs. Ueno, Reuben, and Barcenas at MD Anderson applying QASeq to breast cancer samples have demonstrated the unique capabilities of QASeq.” QASeq provides better sensitivity to CNVs than other NGS solutions. The publication featured collaborative research including clinical sample testing on cfDNA samples from breast cancer patients. CNVs and/or mutations were detected in all patients that had tumor progression.
“CNVs are more difficult to accurately and sensitively detect than other cancer DNA biomarkers, such as single-base mutations or gene fusions, due to the lack of sequence differences,” says David Zhang, co-Founder and General Manager of NuProbe USA, and the corresponding author of the research. “The simultaneous CNV and mutation profiling capabilities of QASeq allow NuProbe to provide our biopharma partners with powerful patient stratification tools. Further down the line, these panels could become companion diagnostics for new drugs.”
NuProbe is a cutting-edge genomics and molecular diagnostics company with revolutionary molecular diagnostic technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe has sites in Houston, USA, Shanghai, China and Suzhou, China. NuProbe’s vision is to offer affordable, timely, and accurate disease state information to enable precision medicine and improve patient outcomes.
NuProbe’s products and services are for Research Use Only and are not intended for In Vitro Diagnostic use.
NuProbe currently offers customized QASeq panels covering up to 50 genes for translational research partners and collaborators. Contact NuProbe’s scientists to see how QASeq can help advance your product development and services.
Wu, L. R. et al. Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling. Nat. Comms. (2022).Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127–1133 (2013).Frampton, G., Fichtenholtz, A., Otto, G. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31, 1023–1031 (2013).
For more than 33 years, investigators in Norton Shores, Michigan, tried to figure out what happened to Stacey Lyn Chahorski, a young woman who left home to travel the country and last spoke to her mother in September 1988.
At the same time, Georgia detectives worked to identify remains that two Department of Transportation employees had discovered near a highway in December 1988.
Both cases soon went cold — until this month.
Authorities with the Dade County Sheriff’s Office in northwestern Georgia and the Georgia Bureau of Investigation (GBI) announced the remains were identified with the help of advanced DNA technology as those of Chahorski and will be soon returned to her family in Michigan.
“Today marks the day where we hunt for the killer now,” GBI Special Agent in Charge Joe Montgomery said in a news conference Thursday. “The biggest problem in being able to solve this case is we had no identity of the victim so we had no starting point. Now we have a starting point and that’s a big jump for us.”
“I think we have a good probability of solving this case and bringing the killer to justice,” he added.
How she was identified
Over the years, GBI agents and Dade County investigators kept going back to the case in hopes of finding an identity, according to a GBI news release.
A forensic artist drew a composite image in hopes that would help lead to an identity. In the mid-2000s, investigators sent additional evidence to an FBI lab for testing, which helped develop a DNA profile — but that didn’t match anyone already in any system.
Meanwhile, authorities in Michigan decided to collect a fingerprint card from Chahorski’s relatives in 2010, a Norton Shores Police Department news release said.
Members of the GBI contacted the FBI again several years later about using investigative genealogy methods to help solve the case. The process usually combines DNA evidence and traditional genealogy to find biological connections between people — in other words, relatives.
For this effort, they enlisted Othram, a Texas-based laboratory that works with law enforcement and has been credited with helping solve a lengthy list of other cold cases.
The lab helped reveal the identity of “Little Miss Nobody,” a young girl that was discovered more than 60 years ago in an Arizona desert, authorities there announced this month.
Last year, it also helped identify a victim found more than four decades ago in Mississippi, who authorities believe was killed by Samuel Little, America’s most prolific serial killer.
“Without the advancements in DNA technology, we wouldn’t have been able to be of assistance and have this success so we’re grateful for that and for the work Othram did,” FBI Special Agent Tim Burke said in Thursday’s news conference.
Chahorski would have been 52 today, the GBI said.
‘A little bit of peace’
Chahorski had been buried in Dade County since 1989 in an unmarked grave.
Her body will now go back to her family, authorities said.
A few weeks ago, authorities notified her mother, who was the one who reported her missing.
“We were able to notify her and bring her a little bit of peace,” Burke said. “We were also able to provide some jewelry that was found on Stacey back here at the crime scene and return that to her,” he said.
“We look forward to helping in any way with the remaining investigation, and also getting Stacey’s remains back to her loved ones in Michigan so that she can finally rest in peace,” he added.
Glioblastoma, the most aggressive form of brain cancer is commonly treated with surgery, radiation, and chemotherapy. However, a newly published study from the research team at Oncologica the world-leading genetic cancer testing laboratory based in Cambridge UK, explains how their genetic sequencing research into predictive glioblastoma biomarkers can empower patients and doctors with DNA blueprints to make better targeted therapy decisions. This could lead to improved treatment outcomes beyond the current survival rate of 7% within five years of diagnosis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005886/en/
New study of genetic brain cancer biomarkers empowers patients and doctors with DNA blueprints for better targeted therapy decisions. (Photo: Business Wire)
The latest anti-cancer targeted therapies and immunotherapies are directed at the genetic DNA mutations that underlie the development and progression of brain cancer. The latest targeted cancer medicines offer great advantages over standard therapeutic approaches as they directly attack the cancer cells but leave normal cells relatively undisturbed. These new genomic targeted drugs have greater specificity and reduce toxic effects for patients compared to conventional chemotherapy.
The fast implementation of these targeted therapies into routine clinical practice has been constrained by a lack of comprehensive genetic screening for these DNA mutations at diagnosis. Furthermore, the processing of tissue biopsies using formaldehyde and wax embedding for diagnosis, results in fragmentation of the DNA test which makes analysis for mutations a challenge.
In Oncologica’s newly published study Oncologica shows how semiconductor biomarker sequencing can be used to accurately screen the fragmented DNA and RNA from routine glioblastoma biopsy/resection samples. This enables comprehensive DNA profiling to be undertaken in the routine initial diagnostic workflow to link detected mutations to a broad range of potential genomic targeted therapies and immunotherapies, rather than wait to see if standard treatments fail to control the disease.
“We are continually researching new ways to improve the genetic test options at initial diagnosis to provide valuable personalised data to aid targeted cancer treatments” said Dr Marco Loddo, Co-Founder and Scientific Director of Oncologica.
Key findings of the paper are;
Oncologica’s Next generation sequencing platform captures 764 of the leading anti-cancer targeted medicine drug combinations and immunotherapies via analysis of actionable genomic mutations across 505 genes. Analysis was performed across 55 glioblastoma patients.
166 actionable mutations were detected across 36 genes linked to 17 off label targeted therapy protocols and 111 clinical trials.
Most patients had 3 or more actionable mutations affecting key cancer regulatory networks including mitogenic signalling pathways, DNA-damage repair pathways and cell cycle checkpoints. Linkage with immunotherapy and PARP inhibitors was identified in 44% of glioblastoma patients because of alterations in DNA-damage repair genes.
The study shows that semiconductor sequencing for actionable mutations can be used to identify a broad therapeutic armamentarium of targeted therapies and immunotherapies that can be potentially employed for the improved clinical management of glioblastoma patients.
“We hope our data will help inform oncologists about the broad range of potential therapies that are now available and that this will translate into improved clinical outcomes for glioblastoma patients in the future said Professor Gareth Williams, Co-Founder and Medical Director at Oncologica.
Read more at www.oncologica.com/news/Newspage and https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0245817
Oncologica is a world leading precision cancer medicine and genomic contract research laboratory based in Cambridge, UK. Our personalised DNA profiling is used to aid identification of the most appropriate targeted therapies for patients with cancer as an alternative to chemotherapy.
Our molecular testing capabilities now cover cancer screening, tumour DNA sequencing, Covid -19 mutation profiling and allergen testing, with over 5 million genetic health tests performed during the last two years. Oncologica’s comprehensive NGS DNA profiling with linkage to targeted therapies provides detailed genomic blueprints that optimize therapy choices, improve health outcomes and help people avoid treatment unlikely to be of benefit.
Oncologica’s contract research programmes, clinical trials, and diagnostic test validation platforms focus on novel genomic therapeutic solutions. The personalised genomic data is helping to empower patients and clinicians to improve treatment outcomes and human health.
Oncologica UK Ltd, Suite 2, The Newnham Building, Chesterford Research Park, CAMBRIDGE UK CB10 1XL. www.oncologica.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20220324005886/en/
CONTACT: Press interviews: Dr Marco Loddo BSc PhD, Co-Founder and Scientific Director
Laboratory Stein is part of the Limbach Group, which is the largest network of laboratories in Germany and one of the largest networks of laboratories in Europe Laboratory MVZ Dr. Stein + Kollegen processes over five million samples annually with a team of 500 employees that includes biologists, chemists, doctors and other specialists
BERKELEY, Calif. and MAINZ, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Labor MVZ Dr. Stein + Kollegen (“Laboratory Mönchengladbach”). Laboratory Mönchengladbach, one of the largest diagnostics laboratories in the North Rhine-Westphalia region of Germany, will commercialize ColoAlert, Mainz Biomed’s unique, highly efficacious, and easy-to-use detection test for colorectal cancer (CRC).
With a team of over 500 employees that includes biologists, chemists, doctors and other specialists, Laboratory Mönchengladbach services over 2500 physicians, processing over five million samples in total annually and screening approximately 1000 patients per week specifically for CRC.
“As a result of our unique model of engaging in mutually beneficial commercial partnerships with leading laboratories such as MVZ Dr. Stein + Kollegen, Mönchengladbach, we’re able to quickly and effectively expand our national footprint and enable larger populations to benefit from highly efficient and reliable CRC testing,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “We are ideally positioned to further scale operations across Europe and will continue to pursue and engage in beneficial partnerships with the leading diagnostics labs in each jurisdiction being targeted.”
Under the terms of the partnership, Mainz Biomed will co-brand ColoAlert with Laboratory Mönchengladbach, and sell its polymerase chain reaction (PCR) assay kits for advanced colorectal cancer detection, on an on-demand basis for use by Labor Mönchengladbach’s network of physicians and their patients. In order to optimize awareness and adoption, Mainz Biomed and Labor Mönchengladbach will also collaborate to deliver a comprehensive marketing and education campaign to include direct-to-consumer advertising, cross channel promotion to physician networks, webinars and sales representative training.
“As an organization focused on delivering the very best diagnostics solutions to our network, we’ve been highly impressed by the efficacy of the ColoAlert test. We’re thrilled to be able to make it available to patients via their physicians across the region and catch more cases of this deadly disease in its earliest stages where it can be successfully treated,” said Dr. Dietmar Dreßen, Managing Director, Laboratory Mönchengladbach.
ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemistry test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the Europe Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.
Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late-stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimates that in 2021 there will be approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death. Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the US should be conducted once every three years starting at age 45. Currently there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these US-based 50+ populations every three years as prescribed equates to a US market opportunity of approximately $3.7 Billion per year.
About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021 as well as the Prospectus filed on January 21, 2022. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
Canada’s food safety watchdog says the discovery of avian influenza in a commercial poultry flock in Nova Scotia has resulted in international trade restrictions on some Canadian poultry products.
The Canadian Food Inspection Agency says the outbreak of high pathogenic H5N1 was reported last week to the World Organization for Animal Health.
The agency says in a news release on Wednesday that the detection has resulted in Canada’s animal health status being changed to say it is not free from avian influenza.
South Korea and the Philippines have imposed restrictions on poultry products from all of Canada including live poultry, poultry meat and edible eggs.
The United States, European Union, Taiwan, Mexico, Japan and Hong Kong have imposed restrictions on some products from Nova Scotia, or from the specific area of the province affected by the bird flu outbreak.
Russia has imposed restrictions on poultry from both Nova Scotia and on Newfoundland and Labrador, where bird flu was also detected in January and December.
The CFIA has not specified the type of birds affected by the pathogen in the Nova Scotia flock.
The agency has said that avian influenza circulates naturally in birds and can affect food-producing birds including chickens, turkeys, quails, and guinea fowl, as well as pet and wild birds.
Highly pathogenic avian influenza can cause severe illness and death in birds.
This report by The Canadian Press was first published Feb. 9, 2022
JOIN THE CONVERSATION
Anyone can read Conversations, but to contribute, you should be registered Torstar account holder. If you do not yet have a Torstar account, you can create one now (it is free)
Conversations are opinions of our readers and are subject to the Code of Conduct. The Star does not endorse these opinions.